Sigyn Therapeutics
Treating Life Threatening Conditions Precipitated by Cytokine Storm Syndrome

Sigyn Therapeutics is a development-stage technology company headquartered in San Diego, California USA. Their focus is the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome including Sepsis, ARDS and acute forms of liver failure, none of which are currently being addressed with an approved therapy.

The primary indication Sigyn Therapy is focused on is Sepsis, a life-threatening organ dysfunction caused by a dysregulated host response to infection. According to recent report in the Journal Lancet there were 48.9 million cases of Sepsis and 11 million deaths globally in 2017. In that same year, an estimated 20.3 million sepsis cases and 2.9 million deaths were among children younger than 5-years old. Sepsis kills more people around the world than all forms of cancer combined. In the United States, Sepsis is the most common cause of in-hospital deaths with annual costs exceeding $24 billion.

Sigyn Therapy has developed an innovative mechanism that essentially filters pro-inflammatory cytokines, cytokine aggregates and endotoxins from the bloodstream. This rebalances the immune system and allows the body to fight these life-threatening conditions. It is a single-use disposable device designed to work with hemodialysis and continuous renal replacement therapy machines already in hospitals and clinics worldwide.

Led by an experienced team of device developers Sigyn Therapy is currently seeking approval for an IDE in the United States and expects to receive market clearance in less than three years.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.